{
  "data": {
    "indicator": {
      "slug": "ctgov-glp1-registered-trials",
      "name": "Registered interventional GLP-1, incretin multi-agonist and amylin trials",
      "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) on ClinicalTrials.gov, any start date.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2026-09-27",
        "period_label": "as of 27 Sep 2026",
        "value": 1963,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_H69RMD40E7RXNSG3P6HD2F7KS7",
        "url": "https://statorigin.org/stat/stat_H69RMD40E7RXNSG3P6HD2F7KS7",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: All interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes), any start date, as registered on 2026-09-27.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}